V. A. Zelenov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. A. Zelenov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andrey E. Karateev
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - Tatiana Valentinovna Beketova
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic University
2 shared publications - Vadim A. Nesterenko
Nasonova Research Institute of Rheumatology
2 shared publications - Valerii E. Bialik
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - A. A. Mesnyankina
V.A. Nasonova Research Institute of Rheumatology
1 shared publication - A. A. Roskidailo
V.A. Nasonova Research Institute of Rheumatology
1 shared publication
Latest Publications
- Open Access
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 88-94
The role of repeat kidney biopsy in patients with lupus nephritis (case report)
Lupus nephritis (LN) occurs in 35–60% of patients with systemic lupus erythematosus (SLE), often in the early stages of the disease. LN is one of the most severe manifestations of SLE and, if not treated promptly and effectively, can lead to rapid and severe loss of kidney function. Despite modern pharmacotherapy, 5–20% of patients develop end-stage renal failure within 10 years of diagnosis of LN. The main principle of LN therapy is to prevent deterioration of renal function, but a consensus on outcome assessment criteria and clinically relevant short- and long-term goals for LN therapy has not yet been reached. There is increasing evidence of the importance of repeat kidney biopsies to assess the outcomes of the initial phase of therapy and to determine the long-term prognosis of renal failure. It is believed that the information obtained from repeat biopsies can help to make optimal treatment decisions and thus increase the likelihood of achieving a complete renal response in the short term and a more favorable renal prognosis in the long term.We describe a clinical case of a young patient with highly active SLE and morphologically confirmed class IV-S LN. Repeat biopsy and clinical and laboratory examination, had confirmed a clinical and laboratory remission of the disease on the background of the therapy. This made it possible to reduce the dose of methylpednisolone and cytostatic drugs (mycophenolate mofetil) and to discontinue therapy with biologic diseasemodifying antirheumatic drug (rituximab).
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 88-94
Open AccessThe role of repeat kidney biopsy in patients with lupus nephritis (case report)
Lupus nephritis (LN) occurs in 35–60% of patients with systemic lupus erythematosus (SLE), often in the early stages of the disease. LN is one of the most severe manifestations of SLE and, if not treated promptly and effectively, can lead to rapid and severe loss of kidney function. Despite modern pharmacotherapy, 5–20% of patients develop end-stage renal failure within 10 years of diagnosis of LN. The main principle of LN therapy is to prevent deterioration of renal function, but a consensus on outcome assessment criteria and clinically relevant short- and long-term goals for LN therapy has not yet been reached. There is increasing evidence of the importance of repeat kidney biopsies to assess the outcomes of the initial phase of therapy and to determine the long-term prognosis of renal failure. It is believed that the information obtained from repeat biopsies can help to make optimal treatment decisions and thus increase the likelihood of achieving a complete renal response in the short term and a more favorable renal prognosis in the long term.We describe a clinical case of a young patient with highly active SLE and morphologically confirmed class IV-S LN. Repeat biopsy and clinical and laboratory examination, had confirmed a clinical and laboratory remission of the disease on the background of the therapy. This made it possible to reduce the dose of methylpednisolone and cytostatic drugs (mycophenolate mofetil) and to discontinue therapy with biologic diseasemodifying antirheumatic drug (rituximab).
- Open Access
- 6 March 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (1) , 120-128
Variants of impingement syndrome of the shoulder joint
Pain in the shoulder joint is one of the most common reasons for seeking medical help associated with the pathology of the musculoskeletal system. The most common disease in this area that causes chronic pain is impeachment syndrome (IS) of the rotator muscles of the shoulder. The domestic literature describes in sufficient detail surgical and conservative approaches for lesions of the shoulder joint, but there are only a few publications on the types of IS. This review is devoted to the description of all occurring types of compression of the tendons of the muscles of the rotator cuff of the shoulder joint within the framework of IS.
- 6 March 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (1) , 120-128
Open AccessVariants of impingement syndrome of the shoulder joint
Pain in the shoulder joint is one of the most common reasons for seeking medical help associated with the pathology of the musculoskeletal system. The most common disease in this area that causes chronic pain is impeachment syndrome (IS) of the rotator muscles of the shoulder. The domestic literature describes in sufficient detail surgical and conservative approaches for lesions of the shoulder joint, but there are only a few publications on the types of IS. This review is devoted to the description of all occurring types of compression of the tendons of the muscles of the rotator cuff of the shoulder joint within the framework of IS.
- Open Access
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 165-173
Review of guideline for the management of large vessel vasculitis presented in 2021 by the American College of Rheumatology / Vasculitis Foundation
The main statements of the recommendations of the American College of Rheumatology and the Vasculitis Foundation on the treatment of patients with systemic vasculitis of large vessels, published in August 2021, are discussed. As a result of a detailed review of current data, a group of experts proposed 22 recommendations and 2 ungraded position statements for giant cell arteritis (GCA), as well as 20 recommendations and 1 ungraded position statement for Takayasu arteritis (AT), on the basis of which algorithms for the treatment of patients with these diseases are presented. An expansion of the value of genetically engineered biological therapy, primarily tocilizumab in GCA and tumour necrosis factor alpha inhibitors in AT, has been recorded. The new recommendations should not be considered as final standards, but are intended to become the basis for choosing a personalized treatment strategy for patients with large vessels vasculitis and serve as a starting point for further research.
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 165-173
Open AccessReview of guideline for the management of large vessel vasculitis presented in 2021 by the American College of Rheumatology / Vasculitis Foundation
The main statements of the recommendations of the American College of Rheumatology and the Vasculitis Foundation on the treatment of patients with systemic vasculitis of large vessels, published in August 2021, are discussed. As a result of a detailed review of current data, a group of experts proposed 22 recommendations and 2 ungraded position statements for giant cell arteritis (GCA), as well as 20 recommendations and 1 ungraded position statement for Takayasu arteritis (AT), on the basis of which algorithms for the treatment of patients with these diseases are presented. An expansion of the value of genetically engineered biological therapy, primarily tocilizumab in GCA and tumour necrosis factor alpha inhibitors in AT, has been recorded. The new recommendations should not be considered as final standards, but are intended to become the basis for choosing a personalized treatment strategy for patients with large vessels vasculitis and serve as a starting point for further research.
- Open Access
- 1 March 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (1) , 112-117
Evaluation of the effectiveness of intra-articular injections of glucocorticoids in knee synovitis in patients with rheumatic diseases in real clinical practice
Intra-articular injections of glucocorticoids are widely used in the complex therapy of rheumatic diseases (RD). However, there is insufficient data on their effectiveness and safety in real clinical practice.The aim of the study – to evaluate the effectiveness of intra-articular injections of glucocorticoids in rheumatic diseases in real clinical practice.Material and methods. The study group consisted of 290 patients with RD, mainly osteoarthritis (OA) and rheumatoid arthritis (RA) (69.0% – women; age – 55.6±12.6 years), who underwent intra-articular injections of glucocorticoids in the knee joint. Indications for intra-articular injections of glucocorticoids were determined by the attending physicians. The control group consisted of 112 patients with OA (71.4% – women; age 59.3±14.6 years) who underwent a course of intra-articular injections of hyaluronic acid. The result of treatment was evaluated in 2 weeks, 1 and 3 months according to a telephone survey.Result. After 2 weeks, 1 month and 3 months after the intra-articular injections of glucocorticoids, the severity of pain during movement decreased (numerical rating scale (NRS) 0–10; Me [25%; 75%]) from 6.0 [4.0; 8.0] to 1,0 [0; 2,0], 2,0 [1,0; 4,0] and 2.5 [1.0; 4.0] respectively (pConclusions. Intra-articular injections of glucocorticoids are an effective and fairly safe method of short-term treatment of synovitis in rheumatic diseases.
- 1 March 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (1) , 112-117
Open AccessEvaluation of the effectiveness of intra-articular injections of glucocorticoids in knee synovitis in patients with rheumatic diseases in real clinical practice
Intra-articular injections of glucocorticoids are widely used in the complex therapy of rheumatic diseases (RD). However, there is insufficient data on their effectiveness and safety in real clinical practice.The aim of the study – to evaluate the effectiveness of intra-articular injections of glucocorticoids in rheumatic diseases in real clinical practice.Material and methods. The study group consisted of 290 patients with RD, mainly osteoarthritis (OA) and rheumatoid arthritis (RA) (69.0% – women; age – 55.6±12.6 years), who underwent intra-articular injections of glucocorticoids in the knee joint. Indications for intra-articular injections of glucocorticoids were determined by the attending physicians. The control group consisted of 112 patients with OA (71.4% – women; age 59.3±14.6 years) who underwent a course of intra-articular injections of hyaluronic acid. The result of treatment was evaluated in 2 weeks, 1 and 3 months according to a telephone survey.Result. After 2 weeks, 1 month and 3 months after the intra-articular injections of glucocorticoids, the severity of pain during movement decreased (numerical rating scale (NRS) 0–10; Me [25%; 75%]) from 6.0 [4.0; 8.0] to 1,0 [0; 2,0], 2,0 [1,0; 4,0] and 2.5 [1.0; 4.0] respectively (pConclusions. Intra-articular injections of glucocorticoids are an effective and fairly safe method of short-term treatment of synovitis in rheumatic diseases.
- Open Access
- 1 March 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (1) , 91-101
Current imaging techniques in large vessel vasculitis
Instrumental imaging modalities play an important role in the diagnosis, evaluation of treatment efficacy and early detection of recurrences in patients with large vessel systemic vasculitis (SV). There’s no currently available universal imaging modality yielding comprehensive information about large vessels regardless all spectacular progress in rheumatology with associated significant insights into SV pathogenesis, innovative therapeutic strategies and broadened diagnostic approaches. Therefore, standardization of instrumental methods in order to accurately assess the disease activity and recognize timely its’ relapse remains a pending issue in management of patients with large vessel SV.Published in 2018 the EULAR (European League Against Rheumatism) guidelines highlighted a wide range of problems concerning visualization of large vessel lesions in SV, resultant from a systematic analysis of up-to-date scientific achievements and clinical experience. The intent of this publication is to summarize the potential of available imaging modalities for patients with large vessel SV in the context of main provisions in the EULAR guidelines and discuss some controversial issues
- 1 March 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (1) , 91-101
Open AccessCurrent imaging techniques in large vessel vasculitis
Instrumental imaging modalities play an important role in the diagnosis, evaluation of treatment efficacy and early detection of recurrences in patients with large vessel systemic vasculitis (SV). There’s no currently available universal imaging modality yielding comprehensive information about large vessels regardless all spectacular progress in rheumatology with associated significant insights into SV pathogenesis, innovative therapeutic strategies and broadened diagnostic approaches. Therefore, standardization of instrumental methods in order to accurately assess the disease activity and recognize timely its’ relapse remains a pending issue in management of patients with large vessel SV.Published in 2018 the EULAR (European League Against Rheumatism) guidelines highlighted a wide range of problems concerning visualization of large vessel lesions in SV, resultant from a systematic analysis of up-to-date scientific achievements and clinical experience. The intent of this publication is to summarize the potential of available imaging modalities for patients with large vessel SV in the context of main provisions in the EULAR guidelines and discuss some controversial issues